| Gates Takes Stake in Drug Development Microsoft co-founder Bill Gates has made a small investment in a pharmaceutical-software maker, in a bid to reinvigorate a quest to use computers to revolutionize drug development. online.wsj.com |
Abbott to Pay Neurocrine Up to $575 Million Abbott Labs agreed to pay as much as $575 million as part of a deal to help develop and commercialize Neurocrine Biosciences' endometriosis treatment. online.wsj.com |
Early Alzheimer's Diagnosis Yields Savings Early diagnosis of cognitive impairment can yield substantial savings in medical costs for Alzheimer's patients, according to a new study. online.wsj.com |
A Look at Immunogen Beyond the T-DM1 Setback Ohad Hammer submits:The FDA’s decision to reject Roche’s (RHHBY.PK) filing for accelerated approval of T-DM1 had quite an impact on Immunogen’s (IMGN) stock. There is no doubt that T-DM1 represents the company’s most valuable program, even if it is in the form of a mid single digit royalty rate, due to its blockbuster potential and impressive clinical activity. This justifies to some extent last week’s market reaction, as the next potential approval for T-DM1 is anticipated in mid 2012. Nevertheless, T-DM1 is facing multiple potential value creation events in the coming year, including an important data set for T-DM1 next month. In addition, the company is involved in 6 clinical stage programs (#7 is expected to enter the clinic this month), some of which are expected to generate data in the coming months. Although none of these programs is nearly as exciting as T-DM1, some of them could become more attractive with time. T-DM1 related eventsComplete Story » seekingalpha.com |
A Genetic Test for Prospective Parents The Bronze award in The Wall Street Journal's 2010 Technology Innovation Awards goes to Counsyl for its simple, low-cost test to detect genes in prospective parents that could cause hereditary diseases in their children. online.wsj.com |